
A New HIV Vaccine Strategy
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
About this listen
Vidcast: https://www.instagram.com/p/DJ94Fy6NTak/
The new vaccine goal: trigger a special type of antibody called broadly neutralizing antibodies (bNAbs) that capably target the lipid membrane surrounding the Human Immunodeficiency Virus. In so doing, they are able to bind to a hidden part of the virus called MPER, which stands for Membrane-Proximal External Region. This zone plays a critical role by permitting the virus to attach, fuse, and inject its genetic material into human cells.
Computational biologists at San Diego’s La Jolla Scripps Research Institute now publish their vaccine blueprint in the journal eLife. Using computer modeling, they demonstrate that certain structural features in the antibodies help them safely recognize viral lipids without endangering normal cells. Their models also predict that maturation of this type of antibody over time leads to better viral binding without creating autoimmunity.
This research data is slated to help design vaccines to harness human immunity for effective and continuing production of these broadly neutralizing antibodies. This vaccine approach appears successful and will be preventing dreaded HIV infections….someday soon.
https://elifesciences.org/articles/90139
https://medicalxpress.com/news/2025-05-antibodies-lipids-path-hiv-vaccines.html
#HIV #vaccines #bNAbs #MPER #aids